2-氯-4-羟基苯甲酸甲酯 | 104253-44-3

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-4-羟基苯甲酸甲酯
• 英文名称: methyl 2-chloro-4-hydroxy-benzoate
• 英文别名: methyl 2-chloro-4-hydroxybenzoate；2-chloro-4-hydroxy-benzoic acid methyl ester；2-chloro-4-hydroxybenzoic acid methyl ester；methyl 4-hydroxy-2-chlorobenzoate
• CAS: 104253-44-3
• 化学式: C₈H₇ClO₃
• mdl: MFCD04117954
• 分子量: 186.595
• InChiKey: BJZFMXJQJZUATE-UHFFFAOYSA-N

物化性质

• 沸点：
  298.3±20.0 °C(Predicted)
• 密度：
  1.354±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温和干燥环境

反应信息

• 作为反应物：
  描述：

  2-氯-4-羟基苯甲酸甲酯 在 吡啶 、 叠氮磷酸二苯酯 、 水 、 sodium carbonate 、 potassium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 47.5h， 生成 乐伐替尼
  参考文献：
  名称：

  一种乐伐替尼的合成方法

  摘要：

  本发明涉及一种乐伐替尼的合成方法，以2‑氯‑4‑羟基苯甲酸甲酯和4‑氯‑7‑甲氧基喹啉‑6‑酰胺为起始原料，经取代反应得到4‑[3‑氯‑4‑甲氧羰基苯氧基]‑7‑甲氧基‑6‑喹啉甲酰胺，再进行碱解反应得到4‑(3‑氯‑4‑羧基苯氧基)‑7‑甲氧基‑6‑喹啉甲酰胺，最后与叠氮磷酸二苯酯(DPPA)发生Curtius重排反应，继而与环丙胺反应一锅法得到乐伐替尼。本发明提供了合成乐伐替尼的新方法，该方法反应步骤简洁，原料简单易得，操作简单，生产成本低。

  公开号：

  CN113307767A
• 作为产物：
  描述：

  4-氨基-2-氯苯甲酸 在 氯化亚砜 、 硫酸 、 sodium nitrite 作用下， 反应 16.25h， 生成 2-氯-4-羟基苯甲酸甲酯
  参考文献：
  名称：

  Optimization of Alkylidene Hydrazide Based Human Glucagon Receptor Antagonists. Discovery of the Highly Potent and Orally Available 3-Cyano-4-hydroxybenzoic Acid [1-(2,3,5,6-Tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide

  摘要：

  Highly potent human glucagon receptor (hGluR) antagonists have been prepared employing both medicinal chemistry and targeted libraries based on modification of the core (proximal) dimethoxyphenyl group, the benzyl ether linkage, as well as the (distal) benzylic aryl group of the lead 2, 3-eyano-4-hydroxybenzoic acid (3,5-dimethoxy-4-isopropylbenzyloxybenzylidene)hydrazide. Electron-rich proximal aryl moieties such as mono- and dimethoxy benzenes, naphthalenes, and indoles were found to be active. The SAR was found to be quite insensitive regarding the linkage to the distal aryl group, since long and short as well as polar and apolar linkers gave highly potent compounds. The presence of a distal aryl group was not crucial for obtaining high binding affinity to the hGluR. In many cases, however, the affinity could be further optimized with substituted distal aryl groups. Representative compounds have been tested for in vitro metabolism, and structure-metabolism relationships are described. These efforts lead to the discovery of 74, NNC 25-2504, 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylenelhydrazide, with low in vitro metabolic turnover. 74 was a highly potent noncompetitive antagonist of the human glucagon receptor (IC50 = 2.3 nM, K-B = 760 pM) and of the isolated rat receptor IC50 = 430 pM, K-B = 380 pM). Glucagon-stimulated glucose production from isolated primary rat hepatocytes was inhibited competitively by 74 (K-i = 14 nM). This compound was orally available in dogs (F-po = 15%) and was active in a glucagon-challenged rat model of hyperglucagonemia and hyperglycemia.

  DOI：

  10.1021/jm0208572

文献信息

• [EN] NEW PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS<br/>[FR] NOUVEAUX DÉRIVÉS D'ACIDE PYRROLIDINE-2-CARBOXYLIQUE POUR LE TRAITEMENT DE LA DOULEUR ET D'ÉTATS PATHOLOGIQUES ASSOCIÉS À LA DOULEUR
  申请人：ESTEVE PHARMACEUTICALS SA

  公开号：WO2020120539A1

  公开（公告）日：2020-06-18

  The present invention relates to new compounds that show pharmacological dual activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the µ-opiod receptor (MOR or mu-opioid). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments (formula (I)).

  本发明涉及显示对电压门控钙通道（VGCC）的α2δ亚基，特别是电压门控钙通道的α2δ-1亚基，以及µ-阿片受体（MOR或μ-阿片）具有药理双重活性的新化合物。该发明还涉及所述化合物的制备过程，以及包含它们的组合物，以及它们作为药物的用途（公式（I））。
• Benzamide derivatives and their constrained analogs as histamine H 3 receptor antagonists
  作者：Ramakrishna Nirogi、Anil Shinde、Vinaykumar Tiriveedhi、Laxman Kota、Sangram Keshari Saraf、Rajesh Kumar Badange、Abdul Rasheed Mohammed、Ramkumar Subramanian、Nageshwararao Muddana、Gopinadh Bhyrapuneni、Renny Abraham

  DOI：10.1016/j.ejmech.2015.12.005

  日期：2016.1

  A series of 4-(1-substituted piperidin-4-yloxy) benzamides and 6-(1-substituted piperidin-4-yloxy)-3,4-dihydro-2H-isoquinolin-1-one derivatives have been synthesized and tested for their binding affinity towards H3 receptor. Most of these synthesized compounds have displayed potent binding affinity for H3 receptor when tested in in vitro binding assay. Preliminary SAR studies, functional activity,

  合成了一系列的4-（1-取代的哌啶-4-基氧基）苯甲酰胺和6-（1-取代的哌啶-4-基氧基）-3,4-二氢-2H-异喹啉-1-酮衍生物，并对其进行了测试。它们对H 3受体的结合亲和力。当在体外结合试验中测试时，这些合成的化合物中的大多数已显示出对H 3受体的有效结合亲和力。SAR的初步研究，功能活性，药代动力学特征和功效特征构成了本通报的主题。
• [EN] MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES MACROCYCLIQUES À LARGE SPECTRE
  申请人：RQX PHARMACEUTICALS INC

  公开号：WO2017084630A1

  公开（公告）日：2017-05-26

  Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

  本文提供了抗菌化合物，其中在某些实施例中，这些化合物具有广谱生物活性。在各种实施例中，这些化合物通过抑制细菌类型1信号肽酶（SpsB）发挥作用，这是细菌中的一种必需蛋白质。还提供了使用所述化合物的药物组合物和治疗方法。
• [EN] AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS AMINO-PYRROLOPYRIMIDINONE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARQULE INC

  公开号：WO2018039310A1

  公开（公告）日：2018-03-01

  The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.

  该申请涉及式(I)的化合物：或其药物可接受的盐、水合物、溶剂化物、前药、立体异构体或互变异构体，其调节BTK的活性，一种包含式(I)化合物的药物组合物，以及一种治疗或预防BTK发挥作用的疾病的方法。
• [EN] AROMATIC RING COMPOUND<br/>[FR] COMPOSÉ À NOYAU AROMATIQUE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013125732A1

  公开（公告）日：2013-08-29

  The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有GOAT抑制作用的化合物，该化合物用于预防或治疗肥胖等疾病，并具有优异的疗效。本发明的化合物由式(I)表示：其中每个符号如说明书中所定义，或其盐。